- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Jazz Pharmaceuticals PLC (JAZZ)
The Jazz Pharmaceuticals share price today is 234.76, view NASDAQ JAZZ stock exchange data. Track the latest Jazz Pharmaceuticals share price with real-time updates on JAZZ stock performance including market cap, day range, 52-week range and dividend yield. Access JAZZ charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
225.50
237.76
52 wk Range
132.10
266.38
JAZZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
225.50237.76
52 wk Range
132.10266.38
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JAZZ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
295.91
Upside
+26.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
20 Buy
2 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 295.91
(+26.05% Upside)
Jazz Pharmaceuticals PLC SWOT Analysis
Revenue Milestone | Jazz Pharmaceuticals achieves record-breaking quarterly revenue, surpassing $1 billion, driven by strong performance of key neuroscience products |
Pipeline Potential | Explore Jazz's promising late-stage programs, including zanidatamab for gastroesophageal cancer and suvecaltamide for essential tremo |
Market Positioning | Delve into Jazz's strategic focus on large market opportunities in sleep disorders, epilepsy, and oncology, positioning for long-term revenue expansion |
Analyst Outlook | Analyst price targets range from $140 to $200, reflecting varied perspectives on Jazz's growth potential and competitive positioning |
Jazz Pharmaceuticals PLC Earnings Call Summary for Q3/2026
- Jazz posted record Q3 revenue of $1.24B, up 10% YoY, beating estimates by $40M; EPS loss of $3.88 vs. forecast of $6.30 due to $754M Actio IPR&D charge.
- Company raised 2026 revenue guidance to $4.775B-$4.85B, implying 13% growth at midpoint; non-GAAP gross margin outlook lifted to 90.5%-91.5%.
- Xywav sales hit $483M with 425 net patient additions; generic competition showed minimal impact as high-sodium alternatives gained limited traction.
- Ziihera launched in HER2-positive gastric cancer with strong early uptake; September saw 3x increase in ordering accounts, 80% from community settings.
- Jazz ended quarter with $2.9B cash and generated $1.3B operating cash flow in nine months; key catalysts include ABS-1230 data in Q4 2026 and ACTION trial H1 2027.
Last Updated: 03-11-2026, 04:14 am
Read Full TranscriptEarnings
Latest Release
02-11-2026
EPS / Forecast
-3.88 / 6.30
Revenue / Forecast
1.24B / 1.2B
Compare JAZZ to Peers and Sector
Metrics to compare | JAZZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJAZZPeersSector | |
|---|---|---|---|---|
P/E Ratio | 73.2x | 25.3x | −0.2x | |
PEG Ratio | 0.48 | −0.03 | 0.00 | |
Price/Book | 3.6x | 3.9x | 2.6x | |
Price / LTM Sales | 3.2x | 4.0x | 2.8x | |
Upside (Analyst Target) | 26.2% | −10.9% | 65.6% | |
Fair Value Upside | Unlock | 1.5% | 10.0% | Unlock |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Jazz Pharmaceuticals (JAZZ) Share Price Today?
The Jazz Pharmaceuticals share price today is 234.76.
What is the current Jazz Pharmaceuticals (JAZZ) share price and day range?
As of 07-11-2026, the Jazz Pharmaceuticals share price is 234.76, with a previous close of 227.32. The share price has ranged from 225.50 to 237.76 today, while the 52-week range spans from 132.10 to 266.38.
What Is the Jazz Pharmaceuticals Market Cap?
As of today, Jazz Pharmaceuticals market cap is 14.59B.
What Is the Jazz Pharmaceuticals (JAZZ) Share Price Target?
The average 12-month share price target for Jazz Pharmaceuticals is 295.91, with a high estimate of 327 and a low estimate of 225. 20 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +26.05% Upside potential.
What Is Jazz Pharmaceuticals's Earnings Per Share (TTM)?
The Jazz Pharmaceuticals EPS (TTM) is 3.28.
When Is the Next Jazz Pharmaceuticals Earnings Date?
Jazz Pharmaceuticals will release its next earnings report on 02-03-2027.
From a Technical Analysis Perspective, Is JAZZ a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Jazz Pharmaceuticals Trade On?
Jazz Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Jazz Pharmaceuticals?
The stock symbol for Jazz Pharmaceuticals is "JAZZ."
How Many Times Has Jazz Pharmaceuticals Stock Split?
Jazz Pharmaceuticals has split 0 times.
How Many Employees Does Jazz Pharmaceuticals Have?
Jazz Pharmaceuticals has 2890 employees.
What Is the JAZZ Premarket Price?
JAZZ's last pre-market stock price is 228.00. The pre-market share volume is 620.00, and the stock has changed by 0.68, or 0.30%.
What Is the JAZZ After Hours Price?
JAZZ's last after hours stock price is 237.00, the stock has changed by 2.24, or 0.95%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.